Olivia Lin, Ph.D., is the Executive Director and co-founder of Studio 1 Labs. With her background in cognitive psychology and analytics, she advances Studio 1 Labs' functional bed sheet for AI applications and works closely with researchers and collaborators for scientific validation. She manages internal relations and oversees the product development cycle including textile manufacturing, software and advanced analytics.
Studio 1 Labs
Edward is Managing Director and co-founder of Studio 1 Labs. Edward’s expertise is in business solutions starting with building exponential technologies made in Canada, leveraging partnerships by taking a medical device idea towards clinical validation and creating channels for adoption and implementation into healthcare institutions. Edward established formal collaborations and applied for grants to raise funds for development and clinical validation with industry, academic, and institutional partners.
Barron Lau is Chief Operations Officer of Studio 1 Labs. Barron is a serial entrepreneur with expertise in global operations that successfully built product and service companies from manufacturing, to global implementation, to acquisition. Large brand retailers that are part of Barron’s client list include Walmart, Target, Toys”R”Us, Yahoo, and Calvin Klein. Barron is overlooking the commercialization of a medical device as the first industry implementation while advancing the agenda for expansion into vertical industries.
Yevgeniy Davletshin, Ph.D, is a Computational Physicist with expertise in mathematical modeling. Smart fabric technology is an emerging field with worldwide researchers conducting characterization studies to better understand the electrical properties of conductive textiles. Yevgeniy’s skills provide understanding of the materials within a range of accuracy on the nanoparticle level which will save on research and development costs, by finding the most optimal design and combination of materials based on our proprietary method of measuring signal variability. His expertise in mathematical modeling will also create new machine learning algorithms that have a high probability of successful predictions.
Studio 1 Labs
Board of Advisors
Markus is a Venture Capitalist within IBM Corporate Strategy at CHQ. He is responsible for working across IBM to design, develop and support PoC proposals with IBM teams and customers. Markus specializes in the Internet of Things projects and also brings 15+ years of consulting and implementation experience in SAP and Mobile on global projects, as well as skills as a software engineer. He has a keen interest in debating and predicting The Next Big Thing in technology.
Dinaro has 10+ years of experience in marketing, business development and partnerships spanning across B2B and B2C segments in the retail, financial services, and startup space. He was director of market development and partnerships for digital payments at MasterCard Canada, where he was responsible for driving digital adoption and strategic alliances with large-scale retailers, FI’s and payment service providers. Prior to MasterCard, Dinaro led business development and partnerships at RedFlagDeals.com, a loyalty and deal content venture (acquired by The Yellow Pages Group). Prior to RedFlagDeals, he had broad oversight and accountability for Dell Canada’s, SMB digital marketing portfolio.
He currently sits on the board of ACT Canada and Blockchain Canada on behalf of MaRS to continue to build relationships with financial institutions and the venture community with the goal of supporting programs related to innovation, payments, commerce, cryptocurrencies and Blockchain.
Dr. Thomas Sull is an emergency room physician currently practicing at Mackenzie Health in Richmond Hill, Ontario. He received his medical degree from the University of Toronto and completed residency training at McMaster University. Previous administrative roles include Vice President and President of the Professional Staff Association at Mackenzie Health. During his undergraduate years, he participated in a significant amount of science research leading to a primary authorship in a peer-reviewed scientific journal.